Silence Therapeutics extends cash runway into 2027; will require partner for zerlasiran Phase 3

Silence Therapeutics plc

2024-FY EPS reported -$0.33 revenue$43,258,000

Net loss of $45.3M ($0.33 per share) for FY2024, compared to $54.2M loss in FY2023.
Cash, cash equivalents and short-term investments of $147.3M at Dec 31, 2024.
Collaboration revenue $43.1M (up $12.2M YoY); R&D expenses $67.9M (up $11M).
Zerlasiran Phase 3 CVOT will not start without a partner; cash guidance extended into 2027.
Divesiran Phase 2 PV enrollment expected to complete by end-2025; Hansoh Pharma exited collaboration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.